Comparison of Two Dosages of Heparin Before Extracorporeal Circulation
NCT ID: NCT03752437
Last Updated: 2022-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
150 participants
INTERVENTIONAL
2019-10-01
2021-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
HEParin Antagonisation in Transcatheter Aortic Valve Implantation
NCT05422170
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
NCT02334007
Comparison of Heparin Types; Efficacy and Safety
NCT01343381
Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome
NCT00435487
Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients
NCT00311753
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Real Weight
Injection of 300 IU of heparin based on REAL weight. This injection will be controlled by an ACT (activated clotting time) one minute after the injection.
ACT (Activated Clotting Time)
Measure of ACT in the two arms in order to determine if injection of heparin based on ideal weight is better or not than those one on real weight.
Heparin
300 IU of heparin
Ideal Weight
Injection of 300 IU of heparin based on IDEAL weight. This injection will be controlled by an ACT (activated clotting time) one minute after the injection.
ACT (Activated Clotting Time)
Measure of ACT in the two arms in order to determine if injection of heparin based on ideal weight is better or not than those one on real weight.
Heparin
300 IU of heparin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ACT (Activated Clotting Time)
Measure of ACT in the two arms in order to determine if injection of heparin based on ideal weight is better or not than those one on real weight.
Heparin
300 IU of heparin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Antithrombin III factor \< 75%
* Patient under treatment by heparin IV
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eric DEFLANDRE, MD, PhD, FCCP, FAHA
Head of Department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric Deflandre, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Astes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinique Saint-Luc of Bouge
Namur, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MDKR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.